强化血糖控制对新诊断儿童1型糖尿病胰腺β细胞功能的影响:一项随机临床试验
这项随机双盲试验在美国6个中心纳入113例新诊断1型糖尿病患儿(7-17岁),随机分入强化管理组(使用自动胰岛素输注系统,n=61)或标准 care 组(使用连续葡萄糖监测,n=52),部分体重≥30 kg者还参与口服维拉帕米或安慰剂的析因设计。主要终点为52周时混合餐耐量试验刺激的C肽曲线下面积。结果显示,强化管理组C肽从基线0.57 pmol/mL降至52周0.45 pmol/mL,标准 care 组从0.60降至0.50 pmol/mL,组间差异-0.01(95%CI -0.11至0.10;P=0.89)。52周时目标范围70-180 mg/dL内时间强化组78% vs 标准组64%(校正差异16%,95%CI 10%至22%)。两组各发生1例严重低血糖和1例糖尿病酮症酸中毒。
要点
- 在新诊断7-17岁1型糖尿病患儿中,强化管理(含自动胰岛素输注系统)52周C肽曲线下面积与标准 care 无显著差异(组间差异-0.01 pmol/mL,95%CI -0.11至0.10;P=0.89)。
- 强化管理组52周目标血糖范围70-180 mg/dL内时间为78%,标准 care 组为64%,校正差异16%(95%CI 10%至22%)。
- 两组各发生1例严重低血糖和1例糖尿病酮症酸中毒。
- 强化管理包括使用自动胰岛素输注系统,标准 care 包括使用连续葡萄糖监测。
- 体重≥30 kg的参与者还按析因设计随机接受口服维拉帕米或安慰剂。
适用人群与场景
- 新诊断的1型糖尿病患儿,年龄7至17岁,从诊断到随机化的平均(SD)时间为24(5)天。
- 研究在美国6个中心进行,随机化时间为2020年7月20日至2021年10月13日,随访于2022年9月15日完成。
处置流程与药物剂量
- 强化糖尿病管理包括使用自动胰岛素输注系统。
- 标准 care 包括使用连续葡萄糖监测。
- 体重30 kg或以上的参与者还按析因设计随机接受口服维拉帕米或安慰剂。
研究设计与关键结果
- 随机、双盲临床试验,纳入113例新诊断1型糖尿病患儿(平均[SD]年龄11.8[2.8]岁;49例女性[43%]),108例(96%)完成试验。
- 主要终点52周混合餐耐量试验刺激的C肽曲线下面积:强化管理组从基线0.57 pmol/mL降至0.45 pmol/mL,标准 care 组从0.60 pmol/mL降至0.50 pmol/mL,组间差异-0.01(95%CI -0.11至0.10;P=0.89)。
- 52周时连续葡萄糖监测显示的目标范围70-180 mg/dL内时间:强化管理组78% vs 标准 care 组64%,校正差异16%(95%CI 10%至22%)。
- 每组各发生1例严重低血糖事件和1例糖尿病酮症酸中毒事件。
证据类型、等级与局限
- 证据类型:随机、双盲临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在新诊断7-17岁1型糖尿病患儿中,包含自动胰岛素输注系统的强化管理可实现优异的血糖控制,但未影响52周时胰腺C肽分泌的下降。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Near normalization of glucose levels instituted immediately after diagnosis of type 1 diabetes has been postulated to preserve pancreatic beta cell function by reducing glucotoxicity. Previous studies have been hampered by an inability to achieve tight glycemic goals.
OBJECTIVE: To determine the effectiveness of intensive diabetes management to achieve near normalization of glucose levels on preservation of pancreatic beta cell function in youth with newly diagnosed type 1 diabetes.
DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, clinical trial was conducted at 6 centers in the US (randomizations from July 20, 2020, to October 13, 2021; follow-up completed September 15, 2022) and included youths with newly diagnosed type 1 diabetes aged 7 to 17 years.
INTERVENTIONS: Random assignment to intensive diabetes management, which included use of an automated insulin delivery system (n = 61), or standard care, which included use of a continuous glucose monitor (n = 52), as part of a factorial design in which participants weighing 30 kg or more also were assigned to receive either oral verapamil or placebo.
MAIN OUTCOMES AND MEASURES: The primary outcome was mixed-meal tolerance test-stimulated C-peptide area under the curve (a measure of pancreatic beta cell function) 52 weeks from diagnosis.
RESULTS: Among 113 participants (mean [SD] age, 11.8 [2.8] years; 49 females [43%]; mean [SD] time from diagnosis to randomization, 24 [5] days), 108 (96%) completed the trial. The mean C-peptide area under the curve decreased from 0.57 pmol/mL at baseline to 0.45 pmol/mL at 52 weeks in the intensive management group, and from 0.60 to 0.50 pmol/mL in the standard care group (treatment group difference, -0.01 [95% CI, -0.11 to 0.10]; P = .89). The mean time in the target range of 70 to 180 mg/dL, measured with continuous glucose monitoring, at 52 weeks was 78% in the intensive management group vs 64% in the standard care group (adjusted difference, 16% [95% CI, 10% to 22%]). One severe hypoglycemia event and 1 diabetic ketoacidosis event occurred in each group.
CONCLUSIONS AND RELEVANCE: In youths with newly diagnosed type 1 diabetes, intensive diabetes management, which included automated insulin delivery, achieved excellent glucose control but did not affect the decline in pancreatic C-peptide secretion at 52 weeks.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04233034.
参考来源
- McVean J, Forlenza GP, Beck RW, et al. Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2023. PMID: 36826834. doi:10.1001/jama.2023.2063
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。